Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04575935 · ClinicalTrials.gov registry record · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
A Phase 3 study of Ovarian Endometrioid Adenocarcinoma and Advanced Ovarian Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 580
- Enrollment target
- 19
- Study locations
NCT04575935 is a Phase 3 study of Ovarian Endometrioid Adenocarcinoma and Advanced Ovarian Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 580 participants, above the 263-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (121% higher). The trial reports 19 study locations across 9 states.
The verdict
NCT04575935, a Phase 3 study of Ovarian Endometrioid Adenocarcinoma and Advanced Ovarian Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 580 participants
- Enrollment target
- 19
- Study locations
Study Summary
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. Laparotomy is a surgical procedure which allows the doctors to remove some or all of the tumor and check if the disease has spread to other organs in the body. MIS may work the same or better than standard laparotomy after chemotherapy in prolonging the return of the disease and/or improving quality of life after surgery.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Chemotherapy
- PROCEDURE Minimally Invasive Surgery
- PROCEDURE Laparotomy
Study Locations (19)
Other
- Arthur J.E. Child Comprehensive Cancer Centre - Calgary - Calgary
- University Health Network - Princess Margaret Cancer Centre - Toronto
- Sant'Orsola Hospital di Bologna - Bologna
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome
- Instituto Nacional de Cancerología (Mexico) - Tlalpan
- Amsterdam UMC - Locatie AMC | H5Zuid 154 - Amsterdam
Texas
- Lyndon Baines Johnson General - Houston
- Houston Methodist - Houston
- M D Anderson Cancer Center - Houston
Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
- Cleveland Clinic Foundation - Florida - Weston
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- NYU Langone Health - Mineola
- Columbia University Medical Center - New York
North Carolina
- Duke - Durham
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- St. Luke's University Health Network - Bethlehem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04575935
The ClinicalTrials.gov registry entry for NCT04575935 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 263-participant average among 15 other Ovarian Endometrioid Adenocarcinoma trials with a reported enrollment target (121% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04575935 reports 19 study locations spanning 9 distinct geographic areas - top geographies include Other, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT04575935 about?
NCT04575935 is a clinical study titled "Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial". This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small i...
What is the current status of trial NCT04575935?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 580 participants. The study started on 2020-08-05. Estimated completion is 2028-12-31.
What conditions does trial NCT04575935 study?
This clinical trial studies the following conditions: Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma.
What interventions are being tested in trial NCT04575935?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Chemotherapy (DRUG), Minimally Invasive Surgery (PROCEDURE), Laparotomy (PROCEDURE).
Who is sponsoring clinical trial NCT04575935?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04575935 being conducted?
This trial has 19 study locations across Florida, Massachusetts, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
COMPLETED · Phase 3
-
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
RECRUITING · Early Phase 1
-
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
RECRUITING · Phase 2
-
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.